期刊
EPILEPSIA
卷 49, 期 -, 页码 56-62出版社
WILEY
DOI: 10.1111/j.1528-1167.2008.01927.x
关键词
Antiepileptic drugs; Generic substitution; Pharmacokinetics; Bioequivalence
资金
- GSK
- Sanofi-Aventis
- Novartis
- Janssen-Cilag
- Pfizer
- UCB
- Eisai
- Abbott Labs
The role of generic drugs in both the US and global marketplace has been steadily increasing over the last few years. Although generic drugs clearly represent an important economic alternative for many patients, there are reasons for concern in certain disease states. Recently, the substitution of antiepileptic drugs in patients with epilepsy has gained increased attention. Concerns over potential therapeutic inequivalence has prompted many clinicians to question current regulatory requirements for both establishing bioequivalence, as well as product substitution. The objective of this article is to present arguments both for and against the use of generic drugs and practice of generic substitution in patients with epilepsy. Regulatory requirements, pharmacokinetic methodology, and biopharmaceutical considerations are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据